Sign Out
Pharmacology: Pharmacodynamics: Zoledronic acid, a bisphosphonate, is a bone resorption inhibitor that acts primarily on bone (due to its high affinity to bone). Zoledronic acid inhibits osteoclastic activity and induces osteoclast apoptosis resulting in inhibition of bone degeneration. Zoledronic acid also reduces skeletal calcium release induced by various stimulatory factors released by tumors.
Pharmacokinetics: Plasma concentrations of Zoledronate rise rapidly, following an intravenous infusion. Plasma protein binding is low (approximately 22-56%). Zoledronate is not metabolized, and about 23-55% of dose is excreted in urine as unchanged drug. Renal clearance is lower in patients with severe renal impairment. Nonrenal clearance is mainly sequestered to bone. The drug is released systemically via bone turnover.
